Victory Capital Management Inc. Buys 26,560 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Victory Capital Management Inc. lifted its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 88.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,640 shares of the company’s stock after buying an additional 26,560 shares during the quarter. Victory Capital Management Inc.’s holdings in Tyra Biosciences were worth $787,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. US Bancorp DE bought a new position in shares of Tyra Biosciences in the fourth quarter worth about $50,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Tyra Biosciences in the fourth quarter worth about $149,000. Franklin Resources Inc. bought a new position in shares of Tyra Biosciences in the third quarter worth about $278,000. Valence8 US LP bought a new position in shares of Tyra Biosciences in the third quarter worth about $310,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Tyra Biosciences in the third quarter worth about $333,000. Institutional investors own 84.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on TYRA. UBS Group began coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $10.94 on Friday. The stock has a market capitalization of $553.60 million, a PE ratio of -6.79 and a beta of 1.09. The business has a 50 day simple moving average of $13.14 and a two-hundred day simple moving average of $16.83. Tyra Biosciences, Inc. has a 1-year low of $9.93 and a 1-year high of $29.60.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 5,401 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the transaction, the director now owns 443,885 shares in the company, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold 21,998 shares of company stock worth $344,818 in the last quarter. 15.40% of the stock is owned by corporate insiders.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.